Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology
18 janv. 2022 16h05 HE
|
Oncocyte Corporation
Collaboration extends global reach for Thermo Fisher’s rapid next-generation sequencing technology Conference call to be held today at 4:30 pm ET/1:30 pm PT IRVINE, Calif., Jan. 18, 2022 (GLOBE...
Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer
04 janv. 2022 08h00 HE
|
Oncocyte Corporation
Data show DetermaCNI detects recurrence with higher sensitivity than standard of care biomarkers, high sensitivity with very low false positives DetermaCNI is the first clinical-grade test to monitor...
Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocyte’s DetermaIO™ Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer
09 déc. 2021 18h00 HE
|
Oncocyte Corporation
Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most aggressive type of breast cancer DetermaIO...
Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx™ in China
08 déc. 2021 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that...
Oncocyte Corporation Hosting Business Update Call
06 déc. 2021 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021
02 déc. 2021 08h00 HE
|
Oncocyte Corporation
Spotlight poster presentation indicates DetermaIO assay and algorithm is robust across multiple diagnostic platforms, confirms that test predicts response to immunotherapy (atezolizumab) benefit ...
Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
09 nov. 2021 16h05 HE
|
Oncocyte Corporation
Clinical launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor microenvironment and consistently outperforms PD-L1 IHC and other...
Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test
04 nov. 2021 08h00 HE
|
Oncocyte Corporation
DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical studies to date across multiple tissue types, DetermaIO has...
Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection
27 oct. 2021 08h00 HE
|
Oncocyte Corporation
U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe Oncocyte’s recently acquired Therasure Transplant...
Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th
26 oct. 2021 16h05 HE
|
Oncocyte Corporation
IRVINE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...